G1T48 is a proprietary, orally available, selective estrogen receptor degrader (SERD).  In preclinical studies, G1T48 has been shown to be more potent than Faslodex® and to have superior anti-tumor efficacy versus other SERDs in development.  G1T48 is on track for IND/CTA filing in 4Q17.

There is strong scientific rationale and clinical validation supporting the combination of a CDK4/6 inhibitor and a SERD for the treatment of patients with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. G1 is planning to combine G1T38 and G1T48 as an all oral, potentially best-in-class regimen for patients with ER+, HER2- breast cancer.